Clinical Trial Update: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vorapaxar for prevention of heart attack and stroke in acute coronary syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Myocardial Infarction
• Myocardial Ischemia

Drugs mentioned

• Vorapaxar (vorapaxar)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Atherosclerosis, Myocardial Ischemia | Phase 3 | Status: TERMINATED | Results posted: 2014-06-09